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ABSTRACT
Research in the last decade strongly suggests thatmesenchymal stem cell (MSC)-mediated therapeu-
tic benefits aremainly due to their secretome,which has beenproposed as apossible therapeutic tool
for the treatment of Parkinson’s disease (PD). Indeed, it has been shown that theMSC secretome in-
creases neurogenesis and cell survival, and has numerous neuroprotective actions under different
conditions. Additionally, using dynamic culturing conditions (through computer-controlled bioreac-
tors) can furthermodulate theMSCsecretome, thereby generating amorepotentneurotrophic factor
cocktail (i.e., conditioned medium). In this study, we have characterized the MSC secretome by
proteomic-based analysis, investigating its therapeutic effects on the physiological recovery of a 6-
hydroxidopamine (6-OHDA) PD ratmodel. For this purpose, we injectedMSC secretome into the sub-
stantia nigra (SNc) and striatum (STR), characterizing the behavioral performance and determining
histological parameters for injected animals versus untreated groups. We observed that the secre-
tome potentiated the increase of dopaminergic neurons (i.e., tyrosine hydroxylase-positive cells)
and neuronal terminals in the SNc and STR, respectively, thereby supporting the recovery observed
in the Parkinsonian rats’ motor performance outcomes (assessed by rotarod and staircase tests). Fi-
nally, proteomic characterization of theMSC secretome (through combinedmass spectrometry anal-
ysis and Bioplex assays) revealed the presence of important neuroregulatory molecules, namely
cystatin C, glia-derived nexin, galectin-1, pigment epithelium-derived factor, vascular endothelial
growth factor, brain-derived neurotrophic factor, interleukin-6, and glial cell line-derived neurotro-
phic factor. Overall, we concluded that the use of human MSC secretome alone was able to partially
revert themotor phenotype and the neuronal structure of 6-OHDAPDanimals. This indicates that the
human MSC secretome could represent a novel therapeutic for the treatment of PD. STEM CELLS
TRANSLATIONAL MEDICINE 2016;5:1–13
SIGNIFICANCE
It has been suggested that the therapeutic effects of humanmesenchymal stem cells (hMSCs) in cen-
tral nervous system (CNS) regenerative medicine are mediated by the active secretion of bioactive
molecules, which is known as the secretome. This study demonstrated that the injection of hMSC
secretome in a 6-hydroxidopamine Parkinson’s disease (PD) rat model was able to revert the Parkin-
sonian phenotype, potentiating the recovery of dopaminergic neurons in both the substantia nigra
and striatum, thereby supporting the motor recovery observed in the PD rats. This work shows the
modulatory roleof thehMSCsecretome inbrain repair, further indicating that such cell-free therapies
could represent the basis of future strategies for the treatment of PD.
INTRODUCTION
Parkinson’s disease (PD), the second most preva-
lent neurodegenerative disorder worldwide, is
clinically characterized by a progressive degener-
ation of dopaminergic (DA) neurons in several
dopaminergic networks [1, 2]. This process is
most intensively observed in the mesostriatal
pathway at the level of the substantia nigra pars
compacta (SNc) [1–4]. As a result of this neuronal
loss, patients develop several motor complica-
tions, including rigidity, bradykinesia, and postural
instability [5]. The use of levodopa (L-DOPA) has
been considered as the standard treatment for
PD and for the reduction of its major symptoms
[6, 7]. Additionally, in conjunction with L-DOPA
aLife and Health Sciences
Research Institute, School of
Health Sciences, University of
Minho, Braga, Portugal;
bICVS/3B’s - PT Government
Associate Laboratory, Braga/
Guimar~aes, Portugal;
cPharmaceutical Production
Research Facility, Department
of Chemical and Petroleum
Engineering, University of
Calgary, Calgary, Alberta,
Canada; dCenter for
Neuroscience and Cell
Biology and eFaculty of
Sciences and Technology,
University of Coimbra,
Coimbra, Portugal; fBiocant -
Biotechnology Innovation
Center, Cantanhede, Portugal
Correspondence: Anto´nio J.
Salgado, Ph.D., Life and Health
Sciences Research Institute
(ICVS), School of Health Sciences,
University of Minho, 4710-057
Braga, Portugal. Telephone: 351
253 60 49 47; E-Mail: asalgado@
ecsaude.uminho.pt
Received February 4, 2016;
accepted for publication August
9, 2016.
©AlphaMed Press
1066-5099/2016/$20.00/0
http://dx.doi.org/
10.5966/sctm.2016-0071
STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–13 www.StemCellsTM.com ©AlphaMed Press 2016
TISSUE ENGINEERING AND REGENERATIVE MEDICINE
This is an open access article
under the terms of the Creative
Commons Attribution License,
which permits use, distribution
and reproduction in any medium,
provided the original work is
properly cited.
I IFICANCE STATEMENT
7 6 634–646
e-mail: asalgado
Received February 4, 2016;
accepted for publication August
9, 2016; publishedOnline First on
September 22, 2016.
ID: manoharj Time: 16:17 I Path: //chenas03/Cenpro/ApplicationFiles/Journals/Wiley/SCTM/Vol00602/170029/Comp/APPFile/JW-SCTM170029
LLS SL I L I I 7;6:634–646 ww.StemCellsTM.com Oc 2016 The Authors
STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
treatment, the use of dopamine reuptake inhibitors, DA ago-
nists, and muscarinic antagonists also have positive clinical ef-
fects [6, 8]. However, despite these pharmacological advances,
most of these treatments have been shown to be insufficient,
presenting some undesirable side effects, long-term ineffi-
ciency, and the inability to recover lost DA neurons or to pro-
tect the viability of the remaining ones [9–13]. Surgical
treatments, such as deep-brain stimulation, have been applied
as an alternative in patients in whom pharmacological treatment
is no longer effective [11, 14, 15]. However, as with drug treat-
ments, the apparent clinical recovery after surgery does not last
and the progression of the degenerative process is not avoided
[16, 17].
The use of a human mesenchymal stem cell (hMSC)-based
strategy has emerged as a potential alternative therapy for
PD [18–20]. In fact, several studies in PD animal models have
already shown that the transplantation of hMSCs acts as a pro-
moter of neuroprotection and/or neural function [21–23]. For
instance, Venkataramana et al. [24] showed that transplanted
hMSCs, which survived transplantation, integrated into the
brain parenchyma and migrated toward the ipsilateral nigra.
Whereas some reports propose that the differentiation of
hMSCs into DA neurons or neural lineages is the principal out-
come for hMSC-mediated PD recovery, others indicate that this
functional recovery is promoted by the hMSC secretome [25,
26]. Indeed, the secretome hypothesis has stimulated a distinc-
tive perspective for the use of hMSCs as a potential cell-free
therapeutic tool for central nervous system (CNS) regeneration
[25, 27]. The role that the hMSC secretome (i.e., conditioned
medium [CM]) plays in vivo has been investigated in several
studies that have shown that transplanted hMSCs (from different
tissue sources) were able to secrete important trophic factors
such as epidermal growth factor, vascular endothelial growth
factor (VEGF), neurotrophin-3, fibroblast growth factor 2 (FGF-2),
hepatocyte growth factor (HGF), brain-derived neurotrophic
factor (BDNF), stromal-derived factor 1, glial cell line-derived
neurotrophic factor (GDNF), and fibroblast growth factor 20
[22, 28–33]. Moreover, we have recently shown that the ad-
ministration of a single injection of the hMSC secretome into
the dentate gyrus of rat hippocampus, with no further cell
transplantation, was able to increase endogenous cell prolifer-
ation and neuronal cell densities, while simultaneously in-
creasing the tissue levels of FGF-2 [34]. These results, per se,
indicate that the secretome itself could be a possible therapeu-
tic tool for CNS regenerative medicine, and specifically for PD.
Therefore, in the present work, we analyzed the effects of the
hMSC secretome on the DA neuronal cell survival and motor
function in an animal model of PD, as well as identified and
characterized possible new neuroregulatory molecules that
mediate these actions.
METHODS
Expansion of hMSCs in Stirred Computer-Controlled
Bioreactors and Collection of the Secretome
We have observed that the dynamic culture of hMSCs in
computer-controlled suspension bioreactors enriched the neuro-
regulatory properties of their secretome [35]. In this study, we
collected the secretome of hMSCs that were cultured in dynamic
environments.
Preparation of Suspension Bioreactors
ADASGIP Parallel Bioreactor system (Eppendorf, Ju¨lich, Germany,
https://www.eppendorf.com) was used for the expansion of
hMSCs. Before inoculating hMSCs into the DASGIP bioreactors,
the 500-ml suspension bioreactors and modified Teflon four-
paddle impellers (Pharmaceutical Production Research Facility,
University of Calgary, Calgary, ON, Canada, http://pprf.ca/) were
siliconized using Sigmacote (Sigma-Aldrich, St. Louis, MO, http://
www.sigmaaldrich.com) tominimize cell attachment to the sides
of the bioreactor vessel and the impeller. After siliconization and
autoclaving of the vessels, the DASGIP systemwas set up and cali-
brated according to protocols provided by themanufacturer. The
bioreactors were maintained at 37°C, using a heating jacket; 21%
oxygen in the headspace; pH of 7.4, controlled by a gas mixture
connected to oxygen, nitrogen, carbon dioxide, and air tanks;
and agitated at 52 rpm using a magnetic stir plate under the
bioreactors.
Preparation ofMicrocarriers, Inoculation of hMSCs, and
CM Collection
Cytodex 3 microcarriers (GE Healthcare Biosciences, Pittsburgh,
PA, http://www.gelifesciences.com) were used for this study
and were prepared as previously described [35]. hMSCs derived
from bone marrow were expanded in static culture (as described
in Teixeira et al. [35]) for two passages before inoculation into the
DASGIP bioreactors. Cells were then harvested and inoculated in-
to the bioreactors at a density of 24,000 cells per milliliter (based
on the final volume of 500 ml) and the volume of the medium in
bioreactors was maintained at 325 ml for the first 24 hours to in-
crease cell attachment. After 24 hours, culture volume was in-
creased to 500 ml to bring the final microcarrier density to 2.0 g/l.
Cells were cultured on the microcarriers for 72 hours, then
the bioreactors were removed from the DASGIP system and
placed in a biosafety cabinet for 10 minutes to allow the micro-
carriers to settle. The supernatant was removed from the biore-
actors, and the microcarriers were washed once with 100 ml of
Neurobasal-A medium (Thermo Fisher Scientific Life Sciences,
Waltham, MA, http://www.thermofisher.com). Following this,
500 ml of Neurobasal-Amediumwith 1% of kanamycin (Thermo
Fisher Scientific Life Sciences) was added to the bioreactors and
the bioreactors were placed back into the DASGIP control sys-
tem for 24 hours. After 24 hours, the bioreactors were again re-
moved, placed in a biosafety cabinet for 10minutes to allow the
microcarriers to settle, and then the supernatant was harvested
and centrifuged at 300g for 10 minutes to remove any cell de-
bris. This supernatant, called the hMSCs CM (i.e., the secre-
tome), was then placed at 280°C until it was required.
Stereotaxic Surgeries
6-Hydroxidopamine Lesions
Ten-week-old Wistar-Han male rats (approximate weight, 300 g;
Charles River, Barcelona, Spain, http://www.criver.com/) were
housed (2 per cage) and maintained in a controlled environment
at 22°C–24°C and 55% humidity, on 12-hour light/dark cycles and
fed with regular rodents’ chow and tap water ad libitum. Animals
were handled for 1 week before beginning injections to reduce
the stress induced by the surgical procedures. All manipulations
were done after consent from the Portuguese National Author-
ity for animal experimentation, Direç~ao Geral de Veterina´ria
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(ID:DGV28421), and in accordancewith the regulations onanimal
care and experimentation (European Union Directive 2010/63/
EU). Thus, for surgical procedures, under combined ketamine
(75 mg/kg) and medetomidine anesthesia (0.5 mg/kg, i.p.), ani-
mals (n = 36) were placed on a stereotaxic frame (Stoelting,
Wood Dale, IL, http://www.stoeltingco.com) and unilaterally in-
jected, using aHamilton syringewith a 30-gaugeneedle (Hamilton,
Bonaduz, Switzerland, http://www.hamiltoncompany.com),with
either vehicle (sham group, n = 11) or 6-hydroxidopamine
(6-OHDA; n = 25; Sigma-Aldrich) directly into themedial forebrain
bundle (MFB) (coordinates related to Bregma: anteroposterior
[AP], 24.4 mm; medial lateral [ML], +1.0 mm; dorsoventral
[DV], 27.8 mm [1], according to the Paxinos and Watson brain
atlas [36]). This model was chosen because the literature indi-
cates 6-OHDA infusions into the MFB can serve as an important
tool to study neuroprotective therapies for PD, such as the appli-
cation of cell grafts or growth factors (e.g., the hMSC secretome)
[37–39]. Sham animals received 2ml of 0.2mg/ml ascorbic acid in
0.9% of NaCl; 6-OHDA animals were injected with 2ml of 6-OHDA
hydrochloride (4 mg/ml) with 0.2 mg/ml ascorbic acid in 0.9% of
NaCl at a rate of 1.0 ml/minute. After each injection, the needle
was left in place for 4minutes to avoid anybackflowup theneedle
tract. Three weeks after the surgery, behavioral assessment was
performed (Fig. 1).
Surgical Treatment: Injection of hMSC CM
Five weeks after the injection of 6-OHDA, we proceeded to inject
the hMSC secretome. After anesthesia was administered, as de-
scribed in the previous section, animals were placed on a stereo-
taxic frame and unilaterally injected, using an Hamilton syringe
with a 30-gauge needle, with either the vehicle (Neurobasal-Ame-
dium [Thermo Fisher Scientific Life Sciences] with kanamycin; 6-
OHDA group; n = 13), or hMSC CM (6-OHDA_hMSC CM; n = 12)
directly in the SNc (coordinates related to Bregma: AP, 25.3 mm;
ML, +1.8mm;DV,27.4mm)and into fourdifferent striatum (STR) co-
ordinates (AP,21.3 mm; ML, 4.7 mm; DV,24.5 mm and24.0 mm;
AP,20.4mm;ML, 4.3mm;DV,24.5mmand24.0mm;AP, 0.4mm;
ML, 23.1 mm; DV, 24.5 mm and 24.0 mm; AP, 1.3 mm; ML,
2.7mm;DV,24.5mmand24.0mm) [36, 40]. In the SNc, 6-OHDA
animals received 1 injection of either 4.0 ml of Neurobasal-A me-
dium with kanamycin or hMSC secretome (as CM), which was in-
jected at a rate of 1.0ml/minute. In STR, 6-OHDAanimals received
either 2.0 ml of Neurobasal-A medium with kanamycin or hMSC
CMineachof the4coordinates,makinga final volumeof8ml.After
each injection, the needlewas left in place for 8minutes in the SNc,
and4minutes in the STR toavoid anybackflowup theneedle tract.
At 1, 4, and 7 weeks following surgery, behavioral assessment was
performed (Fig. 1).
Behavioral Assessment
RotaRod
Motor coordination and balance of animals (sham, n = 11;
6-OHDA, n = 13; 6-OHDA_hMSC CM, n = 12) was evaluated using
the TSERotaRod System (catalog no. 3376-4R; TSE Systems, Ches-
terfield, MO, http://www.tse-systems.com) under an accelerat-
ing protocol previously described [41]. The first 3 days of
testing served as training for the animals. Following this, animals
underwent a four-trial test under an accelerating protocol start-
ing at 4 rpm and reaching 40 rpm in 5 minutes. Animals were
allowed to rest for at least 20 minutes between each trial. On
day 4, using the same protocol, the animal latency to fall was
recorded.
Skilled Paw-Reaching Test (Staircase Test)
Skilled paw reaching (also called the staircase test) was per-
formedwith double staircase boxes (catalog no. 80300; Campden
Instruments, Lafayette, IN, http://www.campdeninstruments.
com), as previously described [42]. The shape and dimensions
of the boxes were similar to the ones described by Montoya
et al. [43]. Theapparatus consists of a clear chamberwith ahinged
lid that was developed to assess the independent forelimb use in
skilled reaching and grasping tasks. A narrow compartment, with
a central platform running along its length, is connected to this
chamber. The removable double staircase with seven steps on
each side can be inserted in the space between the platform
and the box walls. Five pellets were placed into each well of
thedouble staircase apparatus. On the first 2 days, the rats (sham,
n = 11; 6-OHDA, n = 13; 6-OHDA_hMSC CM, n = 12) were familiar-
izedwith the test and pellets thatwere available for 5 and 10min-
utesondays 1 and2, respectively. During the test session, animals
were kept inside the box and had 15 minutes to reach, retrieve,
and eat food pellets present on the steps. All sessions were per-
formed at the same time of day andwith food-restricted animals.
After each test interval, animals were removed from the staircase
boxes and the uneaten pellets were counted.
Apomorphine Turning Behavior
To test apomorphine-induced turning behavior (rotameter test),
animals’ necks were subcutaneously injected with a solution of
0.05 mg/kg apomorphine hydrochloride (Sigma-Aldrich) dissolved
in1%ofascorbicacid in0.9%ofNaCl,andthenplaced inmetal testing
bowls (MED-RSS, Med Associates, Fairfax, VT, http://www.med-
associates.com) for 45 minutes. The number of contralateral
rotations of the bowl was digitally recorded, which allowed
assessment of the effects of the injection vehicle (0.2 mg/ml
of ascorbic acid in 0.9% of NaCl) and 6-OHDA (with 0.2 mg/ml
of ascorbic acid in 0.9% of NaCl). This test was used to validate
the model (after 6-OHDA injections). Apomorphine is a strong
dopamine agonist, and its repeated use could lead to an over-
stimulation of the dopaminergic system, which could impair
the adequate interpretation of the impact of hMSC secretome
on the functional outcomes of the animals [44–46].
TH Immunohistochemistry
After 13 weeks (including the development of the lesion and
consequent treatment), the animals were killed with sodium
pentobarbital (Eutasil, 60 mg/kg i.p.; Ceva Sau´de Animal, Alge´s,
Portugal, http://www.ceva.pt) and transcardially perfused with
4% paraformaldehyde (Merck, Lisbon, Portugal, http://www.
emdgroup.com) in 0.1Mphosphate-buffered saline (PBS). Stria-
tal and mesencephalon coronal sections, 30 mm thick, were
obtained with a vibratome (model no. VT1000S; Leica Biosys-
tems, Wetzlar, Germany, http://www.leicabiosystems.com).
Four series of consecutive sections were obtained and one
was processed as a free-floating tyrosine hydroxylase (TH) im-
munohistochemistry. Sections were immersed for 20 minutes
in 1 M PBS with 3% H2O2, followed by blocking for 2 hours with
5% fetal calf serum (FCS; Thermo Fisher Scientific Life Sciences)
in 1MPBS. Sections thenwere incubated overnight (at 4°C) with
the rabbit anti-mouse TH primary antibody (1:2,000 [Merck,
Teixeira, Carvalho, Panchalingam et al. 3
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Billerica, MA, http://www.emdmillipore.com]) in 2% of FCS in 1 M
PBS, followed by incubation for 30 minutes with a biotinylated
secondary anti-rabbit antibody, and another 30-minute incuba-
tion with an avidine/biotine complex (Thermo Fisher Scien-
tific Life Sciences). Antigen visualization was performed using
25 mg of 3,39-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich) in 50 ml of Tris-HCl 0.05 M, pH 7.6, with 12.5 ml of
H2O2, and stopped at the desired time. Sections were then
mounted on superfrost slides and thionin countercoloration
was performed.
To ensure a representative sampling among all the animals
when quantifying the SNc TH-positive cells, six identical TH-
labeled sections spanning the entire mesenphalon were cho-
sen, including all the portions of the SNc. Using a bright-field
microscope (model no. BX51; Olympus, Center Valley, PA,
http://www.olympusamerica.com) equipped with a digital
camera (PixeLINK PL-A622, CANIMPEX Enterprises, Halifax,
NS, Canada), and with the help of Visiomorph software
(V2.12.3.0; Visiopharm, Hørsholm, Denmark, http://www.
visiopharm.com), the boundaries of the SNc area were drawn.
The delineation of this region was performed through identifica-
tion of anatomic standard reference points andwith the help of a
rat brain atlas [36]. Samples were analyzed using the Visiomorph
software, and total TH+ cells in the SNc areawere counted in both
hemispheres. Data are presented as the percentage of remaining
TH+ cells in the injected side, compared with control side.
Striatal Fiber-Density Measurement
For estimating TH immunoreactive striatal fibers, total immuno-
reactivity of all TH fibers was measured by densitometry, as
described by Febbraro et al. [47]. For this purpose, 4 TH-
immunostained prosencephalon sections representing the coor-
dinates of injection sites within the striatum were selected and
photographed (31 objective) with an SZX 16 Microscope fitted
to aDP-71 digital camera (bothOlympus). Photoswere converted
to gray scale using the Image J program, version 1.48 (National
Institutes of Health, https://imagej.nih.gov/ij/) and analyzed for
gray intensity after calibrating the software program. This was
done using the “optical density step tablet” to determine the op-
tical density (O.D.) of the selected sections and performed ac-
cording to program instructions. This method provided a gross
estimation of Parkinsonian pathology on lesioned side. From this,
striatumO.D. values were determined in both hemispheres using
a 1.1-mm2 rectangular grid, encompassing the injection sites, as
determined by anatomical references and rat brain atlas [36]. The
corpus callosum (internal control) O.D.was alsomeasured inboth
hemisphere sides to avoid nonspecific background. Thus, TH
striatal-fiber densities were determined by calculating the O.D.
difference between the striatum injected with either hMSC CM
or Neurobasal-A medium, and the corpus callosum; as well as be-
tween the intact striatum and corpus callosum. The extent of the
immunostaining on the lesioned sidewas expressed as a percent-
age of the intact side.
Untargeted Proteomics: Mass Spectrometry Analysis:
IDA and Sequential Window Acquisition of All
Theoretical Mass Spectra (SWATH) Acquisition
Threebiological replicatesofhMSCCMwereprocessedaspreviously
described [35]. Secreted proteins were precipitated from the con-
centratedmediumusing the trichloroacetic acid-acetone procedure
[42]. Sampleswerequantifiedusing the2D-QuantKit (GEHealthcare
Biosciences, Pittsburgh, PA, http://www.gelifesciences.com) and
100mg of protein per sample was subjected to liquid digestionwith
trypsin (2 mg of trypsin per sample) overnight at 37°C [35, 48], and
theformedpeptidesweredesaltedusingOMIXtipswithC18station-
ary phase (Agilent Technologies, Glostrup, Denmark, http://www.
agilent.com)before liquidchromatography-tandemmass spectrom-
etry (LC-MS/MS).
LC-MS/MS analysis was performed as previously detailed [35,
48]onaTripleTOF5600System(SCIEX, Framingham,MA,https://
sciex.com) by performing both information-dependent acquisi-
tion (IDA) and SWATH on the same sample. Peptides were re-
solved by liquid chromatography (nanoLC Ultra 2D; Eksigent,
Dublin, CA, http://www.eksigentllc.com) on a Halo Fused-Core
C18 reverse phase column (300 mm 3 15 cm, 2.7 mm particles,
90 A˚; Eksigent) at 5 ml/minute using an acetonitrile gradient in
0.1% formic acid (2%–35% acetonitrile, in a linear gradient for
25 minutes).
Protein identification from the IDAexperimentswas obtained
by searching against the human and bovine species from UniProt
database using the ProteinPilot software (version 4.5; SCIEX).
An independent false discovery rate (FDR) analysis using the
target-decoy approach provided with ProteinPilot software was
used to assess the quality of the identifications, and positive
Figure 1. Experimental design. The Parkinson’s disease model was induced by a unilateral 6-OHDA injection into themedial forebrain bundle.
Three weeks later, animal behavioral analysis (through RotaRod, staircase, and rotameter tests) was performed to validate the model. After-
ward, animals were treated with the human MSC (hMSC) secretome, which was injected in the substantia nigra and striatum, and at 1, 4, and
7weeks after surgery, and behavioral assessment was performed to address hMSC secretome effects. Abbreviations: MSC,mesenchymal stem
cell; 6-OHDA, 6-hydroxidopamine.
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identifications were considered when identified proteins and
peptides reached a 5% local FDR [49, 50].
Additionally, a specific library of precursor masses and frag-
ment ions created from a pool of hMSC samples, described by
Teixiera et al. [51], was used to performed protein identification
from the SWATH analysis. The chromatographic profiles of the
peptides presented in the MSC library were extracted from the
SWATH-mass spectrometry data using the SWATH processing
plug-in for PeakView (version 2.0.01; SCIEX). Peaks were extracted
(in an extracted-ion chromatogramwindowof 4minutes) for up to
5 target fragment ions of up to 15 peptides per protein. Positive
identification was considered for proteins with at least 1 peptide
with a FDR below 1%. Proteins that were identified in a single bi-
ological replicate were not considered for further analysis and
the final list of hMSC CM-specific proteins was used for functional
characterization of the conditioned medium by Gene Ontology
and Pathways analysis using the Protein Analysis Through
Evolutionary Relationships (PANTHER) classification system
(http://pantherdb.org).
Bioplex-Luminex Analysis
The hMSC CM was first concentrated using a 5-kDa cutoff filter
(Vivaspin; GE Healthcare Biosciences) according to manufac-
turer’s guidelines, as previously described [35]. Following this,
a targeted proteomic analysis for VEGF, nerve growth factor,
BDNF, interleukin-6 (IL-6), and GDNF was performed using a
Bioplex-Luminex assay. Samples were analyzed in a MAGPIX,
Luminex’s xMAP instrument (Luminex, Austin, TX, https://www.
luminexcorp.com), and each factor concentration was calculated
or obtained using Bioplex Manager version 6.1 software (Bio-
Rad Laboratories, Hercules, CA, http://www.bio-rad.com), and
expressed as picograms per milliliter.
Statistical Analysis
Statistical evaluation of the animal apomorphine behavioral test
injection (after 6-OHDA)wasperformedusing Student’s t test. For
RotaRod and staircase tests, upon 6-OHDA and hMSC CM or
Neurobasal-A medium injections, analysis of variance repeated
measures followed by post hoc Bonferroni for multiple compar-
isons was performed using the SPSS statistics program (version
22; IBM, Armonk, NY, http://www.ibm.com). Data are presented
as mean6 SEM. The significance value was set at p, .05.
RESULTS
Phenotypic Characterization of 6-OHDA Lesions
To further evaluate the functional integrity of the animal dopaminer-
gic system after 6-OHDA injection (Fig. 2A), the apomorphine-
induced turning test was performed at the end of the behavioral
assessment. Three weeks after the 6-OHDA injections, we observed
Figure 2. Behavioral characterization of 6-OHDA induced lesions. (A, B):After 3weeks, the injection of 6-OHDA in theMFB (A) led to an intense
turning behavior in the apomorphine-induced turning behavior when compared with sham group (B). 6-OHDA-injected animals also exhibited
significant impairment in motor coordination on the RotaRod test (C) and in the paw-reaching test performance (D, E). For rotameter testing,
n=11 for the shamgroupandn=21 for the6-OHDAgroup. ForRotaRod testing,n=9 for the shamgroupandn=17 for the6-OHDAgroup. For the
staircase test, n = 10 for the sham group and n = 21 for the 6-OHDA group. Data are presented as mean 6 SEM. p, p , .05, ppp, p , .001.
Abbreviations: MFB, medial forebrain bundle; 6-OHDA, 6-hydroxidopamine. sec, seconds; STR, striatum.
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that there was a significantly higher number of apomorphine-
induced turning rotations in the 6-OHDA-injected animals when
compared with the sham group (t = 5.898; p , .001; Fig. 2B).
Assessment of motor performance also revealed deficits after
the 6-OHDA injections. Motor coordination, as assessed by the
RotaRod test, was observed to be impaired in 6-OHDA-injected an-
imals (F(1,24) = 16.72; p, .001;h
2
partial = 0.411; Fig. 2C).Moreover,
in the staircase test (used toassess the forelimbuse and skilledmo-
tor function), we also observed that the 6-OHDA-injected animals
were clearly affected, as indicated by a comparison with the ani-
mals in the sham group (F(1,29) = 50.81; p , .001; h
2
partial =
0.637; Fig. 2D). Finally, in a staircase forced-choice task (in which
animals were forced to choose one of the two staircases), the
6-OHDA-injected animals were found to be significantly impaired
compared with the those in the sham group (right-side t = 6.66;
left-side t = 6.81; p, .001; Fig. 2E).
Transplantationof hMSCCM-AttenuatedMotorDeficits
of 6-OHDA-Injected Animals
To evaluate the effects of the hMSC CM (i.e., the secretome)
in 6-OHDA-injected animals, animal motor performances were
assessed at 1, 4, and 7 weeks after CM injection during the
RotaRod and staircase tests.
For the RotaRod test, after CM injection, statistical analy-
sis showed an effect for the factor treatment (F(2,23) = 31.58;
p , .001; h2partial = 0.733) but no effect for the factor time
(F(1.82, 41.89) = 0.727; p = .477; h
2
partial = 0.031) and no interaction
between these factors (F(3.64, 41.89) = 2.24; p = .087; h
2
partial =
0.163). Comparing the CM-injected animals with the untreated
group (i.e., the 6-OHDA group), post hoc testing revealed that
the motor coordination of the former group significantly im-
proved after hMSC CM injection (p = .016; Fig. 3A). The same im-
provementswerealsoobservedwith the staircase test,whichwas
used to address the forelimb use and for which the success rate
of eaten pellets was evaluated. After the CM injection, statisti-
cal analysis revealed a significant effect for the treatment
(F(2,28) = 48.33; p , .001; h
2
partial = 0.775), for the factor time
(F(2.57, 71.96) = 18.01; p , .001; h
2
partial = 0.391), and the inter-
action between these factors (F(5.14, 71.96) = 6.17;p, .001;h
2
partial =
0.306). Comparing the CM-injected animals with the 6-OHDA
group, post hoc analysis revealed that the injection of hMSC CM
led to a significant improvement of the success rate of eaten pellets
Figure 3. Motor coordination performance after hMSCCM (i.e., secretome) injection into the substantia nigra and striatum. (A): Latency to fall
was measured in the accelerating RotaRod test, demonstrating that the hMSC CM-injected animals had a significant improvement (at 1 and
4 weeks after injection; p, .05) in their motor coordination when compared with the 6-OHDA group 6-OHDA. (B): Paw-reaching performance
(assessed by the staircase test) also demonstrated a significant improvement (at 4 and 7 weeks after injection; p, .05) of the forelimb coor-
dination of the hMSC CM-injected animals when compared with the 6-OHDA group. Even when the animals were submitted to a paw-reaching
forced-performance task, the hMSC CM-injected animals presented a better performance on the affected side (at 4 and 7weeks after injection;
p, .05) when compared with the 6-OHDA group (C, D). For the RotaRod test, the numbers tested in the sham, 6-OHDA, and hMSC CM groups
were 9, 9, and 8, respectively. For staircase test, the numbers tested in the sham, 6-OHDA, and hMSCCMgroupswere 10, 10, and 11, respectively.
Data are presented as mean6 SEM. p, p, .05; #, sham animals statistically different from 6-OHDA- and hMSC CM-injected animals, p, .001.
Abbreviations: hMSC CM, human mesenchymal stem cell-conditioned medium; 6-OHDA, 6-hydroxidopamine; sec, seconds; w, weeks.
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(p = .018; Fig. 3B). In addition, in the forced-choice task, the
hMSC CM-injected animals also had improved performance.
Statistical analysis revealed an effect for the factor treatment
(F(2,28) = 34.06; p , .001; h
2
partial = 0.709), the factor time
(F(2.87, 80.35) = 3.22; p = .029;h
2
partial = 0.103), and the interaction
between these factors (F(5.74, 80.35) = 3.13; p = .009; h
2
partial =
0.183). Post hoc testing of the effects of the hMSCs CM revealed
an increased success rate of eaten pellets (in the affected side)
when compared with the 6-OHDA group (left side, p , .05,
Fig. 3C; right side, p = .438, Fig. 3D).
Transplantation of the hMSC Secretome Restored the
Neuronal Structure
To further analyze the effects of the 6-OHDA injections and the
resulting treatment with hMSC CM, histological analyses for TH
were performed. We found that there was a significant loss of
DA neurons after injection of 6-OHDA into the SNc (Fig.
4A–4C). Indeed, statistical analysis revealed an effect for the
treatment (F(2, 23) = 213.34; p, .001; h
2
partial = 0.949). Injection
of the hMSC CM appeared to play a role in the survival of DA
neurons: There was a significantly higher number of TH-
positive cells observed in the SNc (CM: 25.36% 6 5.45%) when
compared with the 6-OHDA group (5.08% 6 1.60%) (p , .01;
Fig. 4D). The same tendency was also observed in the striatum
(Fig. 4E–4G) by assessing TH-positive fibers by densitometry
analysis. Statistical analysis revealed results from the treatment
(F(2, 23) = 350.69; p, .001; h
2
partial = 0.997) in which the injection
of hMSC CM was able to increase the TH expression levels when
compared with the 6-OHDA group (p, .05; Fig. 4H).
hMSCs Secretome: A Source of Neuroregulatory
Molecules for PD
To identify key molecules in the hMSC secretome that were elic-
iting the favorable behavioral responses in the 6-OHDA-treated
animals, we characterized the secretome through targeted and
nontargetedproteomic approach-based analyses (i.e., Bioplex as-
says and a combinedmass spectrometry approach. From the Bio-
plex analyses, we were able to observe that hMSCs secreted
important neurotrophic factors such as VEGF, BDNF, IL-6, and
GDNF (Fig. 5A). In addition to these findings, and through the
Figure 4. Representative photomicrographs of brain slices stained for TH. Compared with the sham group (A, E), all animals that were
submitted to 6-OHDA injection exhibited reduced TH staining both in the SNc and striatum (STR). However, animals injectedwith the hMSC
CM (i.e., secretome) (C, G) had significantlymore TH-positive stainingwhen comparedwith the 6-OHDA group (B, F). (D):Quantification of
TH-positive cells on SNc revealed approximately 95% degeneration in the 6-OHDA group and approximately 75% in the CM-injected an-
imals. (H): At the STR level, the quantification of TH staining revealed a degeneration of approximately 88% in the 6-OHDA group, and
approximately 77% in the CM-injected animals. Data are presented as mean 6 SEM. There were nine animals in the sham group and
in the 6-OHDA group, and eight in the hMSC CM group. p, p , .05, pp, p , .01; #, sham animals statistically different from 6-OHDA-
and hMSCs CM-injected animals, p, .001. Scale bars = SNc, 200 mm; STR, 1 mm. Abbreviations: Ctr, control; hMSC CM, human mes-
enchymal stem cell-conditioned medium; Ipsi, ipsilateral; 6-OHDA, 6-hydroxidopamine; SNc, substantia nigra pars compacta; SNr,
substantia nigra pars reticulata; TH+, tyrosine hydroxylase positive.
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combinedMS analysis (Fig. 5B), we also found additional proteins
(according to the UniProtKB/Swiss-Prot classification) with im-
portant actions (Fig. 5C, 5D), including CNS regulators such as
Cys C (P01034), glia-derived nexin (GDN; P07093), galectin-1
(Gal-1; P09382), and pigment epithelium-derived factor (PEDF;
P36955) (Table 1).
DISCUSSION
In this study, we used a rat model of PD, based on a unilateral in-
jection of 6-OHDA into the MFB (Fig. 2A) [1, 41]. This model is
characterized by a progressive degeneration of DA neurons, lead-
ing to the appearance of themainmotor symptomsof the disease
[1, 52]. In the apomorphine-turning behavior (Fig. 2B), 6-OHDA-
injected animals displayed an intense turning behavior (p, .001)
when compared with the sham group, indicating a decline in the
functional integrity of the DA system. In addition, we have also
verified that the animals’ motor coordination was affected
(Fig. 2C, 2D), which correlated with previous reports showing im-
paired coordination and skilledmotor function in animalswithDA
lesions [41, 53].
Considering the effects of the hMSC secretome (i.e., the
CM) on motor coordination (as seen in the RotaRod test), we
observed that its injection was able to improve the motor per-
formance of the CM-injected animals when compared with the
6-OHDA group (Fig. 3A). Interestingly, despite these improve-
ments, we also observed that the effects of the hMSC secre-
tome declined over the time, probably through the in situ
consumption of the factors contained in it. Therefore, future
studies should investigate the temporal effects of hMSC se-
creted factors.
In the staircase test, which assessed the paw-reaching motor
function, we observed that hMSC CM injection improved the
success rate of eaten pellets in the CM-injected animals when
compared with the 6-OHDA group (Fig. 3B). Moreover, in the
forced-choice task, the injection of hMSC CM was observed to
Figure 5. The hMSC secretome as a source of neuroregulatorymolecules for PD. (A): Through Bioplex-Luminex-based analysis, wewere able to
observe an active secretion of neurotrophic factors such as VEGF (highly expressed; p , .05), BDNF, IL-6, and GDNF—important regulators/
modulators on dopaminergic neuronal survival and protection. Through a combined MS analysis (B), we also found 61 proteins secreted by
hMSCs that, in accordance with Gene Ontology analysis of biological processes (C) and Protein Analysis Through Evolutionary Relationships
(PANTHER) pathways (D) have neuroregulatory properties such as cystatin C, glia-derived nexin, galectin-1, and pigment epithelium-derived
factor (PEDF) (B). Like the other neurotrophic factors, PEDF was found to be a neuroprotective molecule of the dopaminergic system. Data are
presented as mean6 SEM; n = 3. Abbreviations: BDNF, brain-derived neurotrophic factor; GDNF, glial cell line-derived neurotrophic factor; IDA,
information-dependent acquisition; IGF, insulin-like growth factor; IL-6, interleukin-6; SWATH, Sequential Window Acquisition of All Theo-
retical Mass Spectra; VEGF, vascular endothelial growth factor.
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Table 1. Combined list of reproducible proteins as identified by IDA and SWATH proteomic screenings
Method Accession number Accession name Name
IDA and SWATH P08253 MMP2_HUMAN 72 kDa Type IV collagenase
IDA P68133 | P68032 | P63267 |
P62736
ACTS_HUMAN | ACTC_HUMAN |
ACTH_HUMAN | ACTA_HUMAN
Actin,a skeletalmuscle|actin,a cardiac
muscle 1 |actin, g-enteric smooth
muscle |actin, aortic smooth muscle
IDA and SWATH P60709 ACTB_HUMAN Actin, cytoplasmic 1
IDA and SWATH P43652 AFAM_HUMAN Afamin
IDA and SWATH P02763 A1AG1_HUMAN a-1-Acid glycoprotein 1
IDA and SWATH P01011 AACT_HUMAN a-1-Antichymotrypsin
SWATH P01009 A1AT_HUMAN a-1-Antitrypsin
IDA and SWATH P04217 A1BG_HUMAN a-1B-glycoprotein
IDA and SWATH P02765 FETUA_HUMAN a-2-HS-glycoprotein
IDA P06733 ENOA_HUMAN a-Enolase
IDA and SWATH P02652 APOA2_HUMAN Apolipoprotein A-II
IDA and SWATH P02749 APOH_HUMAN b-2-Glycoprotein 1
SWATH P61769 B2MG_HUMAN b-2-Microglobulin
SWATH P21810 PGS1_HUMAN Biglycan
SWATH P23528 COF1_HUMAN Cofilin-1
IDA and SWATH P02452 CO1A1_HUMAN Collagen a-1(I) chain
IDA P20908 CO5A1_HUMAN Collagen a-1(V) chain
IDA and SWATH P12109 CO6A1_HUMAN Collagen a-1(VI) chain
IDA and SWATH P08123 CO1A2_HUMAN Collagen a-2(I) chain
SWATH P12110 CO6A2_HUMAN Collagen a-2(VI) chain
IDA and SWATH P12111 CO6A3_HUMAN Collagen a-3(VI) chain
IDA P0C0L4 | P0C0L5 CO4A_HUMAN Complement C4-A | complement C4-B
SWATH P01034 CYTC_HUMAN Cystatin-C
SWATH P02751 FINC_HUMAN Fibronectin
IDA and SWATH P23142 FBLN1_HUMAN Fibulin-1
IDA and SWATH Q12841 FSTL1_HUMAN Follistatin-related protein 1
SWATH P09382 LEG1_HUMAN Galectin-1
IDA and SWATH P07093 GDN_HUMAN Glia-derived nexin
IDA P04406 G3P_HUMAN Glyceraldehyde-3-phosphate
dehydrogenase
IDA and SWATH P00738 HPT_HUMAN Haptoglobin
SWATH P69905 HBA_HUMAN Hemoglobin subunit a
IDA and SWATH P68871 HBB_HUMAN Hemoglobin subunit b
IDA and SWATH P02790 HEMO_HUMAN Hemopexin
IDAa Q99880 | Q99879 | Q99877 |
Q93079 | Q5QNW6 | Q16778 |
P62807 | P57053 | P33778 |
P23527 | P06899 | O60814 |
Q96A08
H2B1L_HUMAN | H2B1M_HUMAN |
H2B1N_HUMAN | H2B1H_HUMAN |
H2B3B_HUMAN | H2B2F_HUMAN |
H2B2E_HUMAN | H2B1C_HUMAN |
H2B1D_HUMAN | H2BFS_HUMAN |
H2B1B_HUMAN | H2B1O_HUMAN |
H2B1J_HUMAN | H2B1K_HUMAN |
H2B1A_HUMAN
HistoneH2B type 1-L | histoneH2B type
1-M | histone H2B type 1-N | histone
H2B type 1-H | histone H2B type 3-B |
histoneH2B type 2-F | histoneH2B type
2-E | histone H2B type -C/E/F/G/I |
histoneH2B type1-D|histoneH2B type
F-S | histoneH2B type 1-B | histoneH2B
type1-O|histoneH2B type1-J |histone
H2B type 1-K | histone H2B type 1-DA
SWATH P10915 HPLN1_HUMAN Hyaluronan and proteoglycan link
protein 1
IDA and SWATH P01308 | F8WCM5 INS_HUMAN | INSR2_HUMAN Insulin | insulin, isoform 2
SWATH Q16270 IBP7_HUMAN Insulin-like growth factor-binding
protein 7
IDA and SWATH P19823 ITIH2_HUMAN Intera-trypsin inhibitor heavy chain H2
IDA P02750 A2GL_HUMAN Leucine-rich a-2-glycoprotein
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be an enhancer (on the affected side) of the paw-reaching
motor performance when compared with the 6-OHDA group
(Fig. 3D). Moreover, we also observed that the administra-
tion of the secretome induced an increase on the TH+ neurons
and fibers (Fig. 4), which most likely mediated the positive
functional improvements we observed. Although, to our
knowledge, no reports have been presented with an hMSC
secretome in PD animal models to date, similar results were ob-
served by Cova et al. [28] and Sadan et al. [33] for another ap-
proach whereby MSC cells were transplanted. These authors
correlated animal improvements with the increase in the local
expression of BDNF and GDNF by transplanted MSCs. Recently,
Cerri et al. [54], also supporting the secretome theory, demon-
strated that after transplantation ofMSCs, functional balance of
the dopaminergic system was restored; they attributed these
outcomes to an in situ secretion of BDNF by MSCs.
To further understand which factors present in the hMSCs
secretome could be involved in this phenomena, nontargeted
and targeted proteomic approaches were performed. The lat-
ter revealed that molecules such as VEGF, BDNF, IL-6, and
GDNF (Fig. 5A), described as stronger modulators of dopami-
nergic survival and protection, were present in the hMSC secre-
tome [55–58]. Studies have described VEGF as a promoter
of neuroprotection of DA neurons, by stimulating the neuro-
pilin receptor expressed on DA neurons [59] or through the
activation of glial cells and by promoting angiogenesis [60].
BDNFhas also beendescribed as a credible protectivemolecule
in the degenerative process of PD [55]. In fact, when applied in
vitro, BDNF induced the differentiation and neurite outgrowth
in DA neurons [61]. Indeed, in an organotypic model of PD,
BDNF was also capable of protecting DA neurons from 6-OHDA
treatment, even when applied after the addition of toxin [62].
In vivo, in nonhuman primates, BDNF has demonstrated the
ability to reduce DA neuronal loss, suggesting a significant pro-
tective effect [63]. Such evidence reinforces the importance of
BDNF in PD; from the molecular point of view, it has been sug-
gested that the downregulation of BDNF expression in the SNc
might be one of the earlier steps at the onset of PD, which leads
to an increased sensitization of DA neurons [64]. Secretion of
IL-6 byMSCs has been reported to play important roles in scav-
enging superoxide radicals by increasing the antioxidant en-
zyme activity, through signal transducers and activators of
transcription pathways, leading to the protection of neuronal
cells [56]. Finally, the therapeutic effects of GDNF have largely
been assessed in preclinical and clinical models of PD, leading
to protective effects andmotor performance amelioration [55,
65, 66]. Indeed, in vitro studies have suggested that these
protective effects of GDNF on DA neurons involves the activa-
tion of themitogen-activated protein kinase (MAPK) and phos-
phoinositide 3-kinase (PI3K) intracellular pathways [67]. In
Table 1. (Cont’d)
Method Accession number Accession name Name
IDA and SWATH P01033 TIMP1_HUMAN Metalloproteinase inhibitor 1
SWATH P16035 TIMP2_HUMAN Metalloproteinase inhibitor 2
IDA and SWATH Q96PD5 PGRP2_HUMAN N-acetylmuramoyl-L-alanine amidase
IDA P62937 PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A
IDA and SWATH Q15063 POSTN_HUMAN Periostin
SWATH P36955 PEDF_HUMAN Pigment epithelium-derived factor
IDA and SWATH P05155 IC1_HUMAN Plasma protease C1 inhibitor
IDA and SWATH P05121 PAI1_HUMAN Plasminogen activator inhibitor 1
IDA P07737 PROF1_HUMAN Profilin-1
IDA P14618 KPYM_HUMAN Pyruvate kinase PKM
SWATH P02753 RET4_HUMAN Retinol-binding protein 4
IDA and SWATH P02787 TRFE_HUMAN Serotransferrin
IDA and SWATH P02768 ALBU_HUMAN Serum albumin
IDA and SWATH P09486 SPRC_HUMAN SPARC
SWATH O00391 QSOX1_HUMAN Sulfhydryl oxidase 1
SWATH P07996 TSP1_HUMAN Thrombospondin-1
IDA and SWATH Q15582 BGH3_HUMAN Transforming growth factor-b-induced
protein ig-h3
IDA and SWATH P02766 TTHY_HUMAN Transthyretin
IDA P07477 TRY1_HUMAN Trypsin-1
IDA and SWATH P08670 VIME_HUMAN Vimentin
IDA P04004 VTNC_HUMAN Vitronectin
IDA and SWATH P25311 ZA2G_HUMAN Zinc-a-2-glycoprotein
Sixty-one proteins were found to be secreted, of which, according to Gene Ontology analysis of biological processes and Protein Analysis Through
Evolutionary Relationships (PANTHER) pathways, four have neuroregulatory properties (shown in bold): cystatin C, galectin-1, glia-derived nexin, and
pigment epithelium-derived factor.
aAccording toUniProtKBanalysis, theprotein codeP62807corresponds to theaccessionnameH2B1C_Human,which in turn corresponds to theprotein
name of histone H2B type 1-C/E/F/G/I, as it can be assessed in the UniProtKB database; http://www.uniprot.org/uniprot/P62807.
Abbreviations: IDA, information-dependent acquisition; SWATH, Sequential Window Acquisition of All Theoretical Mass Spectra.
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vivo, it has been demonstrated that the neuroprotective ef-
fects of GDNFweremediated by its capacity to inhibit proapop-
totic molecules such as JNK and p38, and activate prosurvival
Akt andMAPKpathways [68]. In addition to these neuroprotec-
tive effects, GDNF was also described as an antioxidant agent
because it was found to be able to enhance the activity of en-
zymes involved in the detoxification of reactive oxygen species
such as superoxide dismutase, catalase, and glutathione perox-
idase, respectively [69].
However, in addition to thesewell-known neurotrophic fac-
tors, we also found that hMSCs produced additional molecules
(Fig. 5B) with neuroregulatory potential, such as Cys C, GDN,
Gal-1, and PEDF, which have been reported to have important
actions in the migration, differentiation, and neuroprotection
mechanisms both in vitro and in vivo [70–73]. Of these, only
PEDFwas found to be an important neurotrophic and neuropro-
tectivemolecule in the context of PD [73, 74]. This has been con-
firmed by Falk et al. [74], who, when comparing other factors
(e.g., GDNF family) used in the treatment of PD, stated that PEDF
has advantages in the ease of delivery and functional outcomes.
Indeed, recent reports have suggested that upregulation of PEDF
occurs in response to acute insults in the dopaminergic system,
suggesting that PEDF may act as an endogenous neuroprotective
molecule, triggering neuronal survival and behavioral improve-
ments in animal models of PD [74, 75]. These neuroprotective
actions have been correlated by the fact that PEDF is able to
stimulate the activation of the NF-kB signaling cascade, which
allows NF-kB to act as a transcription factor that induces
the expression of factors critical to neuronal protection and
survival, including BDNF and GDNF [74]. Thus, we hypothesize
that the modulating effect on DA neurons triggered by the
hMSCs secretome could be related to the increased presence
or expression of VEGF, BDNF, IL-6, GDNF, and PEDF. Our find-
ings suggest that this stimulation by the hMSC secretome is
not dependent on the presence of just one secreted factor
but several, as noted by our targeted and nontargeted proteo-
mic analyses.
CONCLUSION
After the injection of an enhanced bioreactor-produced hMSC
secretome (i.e., CM), we observed an improvement in animal
behavior when compared with the 6-OHDA group. We also
found that the injection of the hMSC secretome was able to in-
crease the densities of TH-positive cells, a fact that most likely
explains the improved behavioral performance of the CM-
injected animals. In addition to the important neuroregulatory
molecules present in the hMSC CM (e.g., VEGF, BDNF, IL-6, and
GDNF), the presence of PEDF might also have a role in its out-
comes because it has been described as an important neurotro-
phic and neuroprotective molecule in PD. Overall, our results
suggest strongly that the use of the hMSC secretome may be
a new and important tool for the treatment of PD because
the secretome is able to modulate the DA neuronal survival
and animal behavior.
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